Herbs (Global Traditional) · European
Chelidonium majus
Moderate Evidencebotanical2 PubMed Studies
Hermetica Superfood Encyclopedia
Chelidonium majus is a European herb containing alkaloids like chelidonine and sanguinarine that demonstrate immune-modulating and anti-cancer properties. The plant's bioactive compounds work by activating immune cells and inhibiting cancer cell proliferation through multiple cellular pathways.
Chelidonium majus L., commonly known as greater celandine, is a perennial herbaceous plant in the Papaveraceae family, native to Europe and now widely distributed globally. The plant is harvested for its aerial parts and yellow-orange latex-rich root, with extracts typically prepared using 80% ethanol or methanol, sometimes followed by defatting with n-hexane.
Clinical evidence for Chelidonium majus is extremely limited, with no randomized controlled trials or meta-analyses identified. The only human data comes from a small observational case series of 20 COVID-19 outpatients and a 1991 immunostimulation study in cancer patients using Ukrain derivatives (PMID: 1713821). Most research consists of in vitro studies and preliminary animal models (PMID: 26626193).
Limited clinical dosing data exists. In the COVID-19 observational series, 10% mother tincture was used at 20-30 drops orally three times daily for 3-12 days. No standardized RCT dosage ranges have been established. Consult a healthcare provider before starting any new supplement.
Chelidonium majus (greater celandine) is a medicinal herb rather than a food ingredient, so conventional macronutrient profiling is limited; it is not consumed in nutritive quantities. Bioactive alkaloid content is the primary focus: total alkaloid concentration in aerial parts ranges approximately 0.1–1.0% dry weight, with roots containing higher concentrations (up to 2% dry weight). Primary alkaloids include chelidonine (0.1–0.6% dry weight, the dominant alkaloid), coptisine (0.01–0.1% dry weight), berberine (0.01–0.05% dry weight), sanguinarine (0.01–0.08% dry weight), chelerythrine (0.05–0.3% dry weight), and sparteine in trace amounts. Secondary metabolites include flavonoids (quercetin, rutin, kaempferol glycosides; total flavonoid content approximately 0.5–2.0% dry weight), hydroxycinnamic acids (chlorogenic acid, caffeic acid derivatives; approximately 0.3–1.5% dry weight), and chelidonic acid (a pyranone dicarboxylic acid, approximately 0.5–1.0% dry weight). Carotenoids contribute to the characteristic orange latex (beta-carotene, lutein present but unquantified precisely). Minimal conventional nutritional data exists: crude protein is estimated at 10–15% dry weight in leaf material, crude fiber approximately 15–25% dry weight, with negligible fat content. Vitamin C has been detected in fresh aerial parts (approximate range 50–150 mg/100g fresh weight). Bioavailability: alkaloid absorption is pH-dependent and variable; chelidonine and sanguinarine show moderate oral bioavailability but undergo significant first-pass hepatic metabolism. The alkaloid fraction is associated with hepatotoxicity at elevated doses, placing a narrow therapeutic-to-toxic window on any concentrated preparations.
Chelidonium majus alkaloids, particularly chelidonine and sanguinarine, activate peripheral blood mononuclear cells and modulate T-cell populations by increasing CD4+/CD8+ ratios. The antiproliferative effects against cancer cells involve multiple pathways including apoptosis induction and cell cycle arrest. Sanguinarine specifically targets topoisomerase enzymes and disrupts mitochondrial function in malignant cells.
Preliminary human studies show Chelidonium majus can activate immune cells and increase favorable T-cell ratios, though sample sizes and study duration remain limited. In vitro research demonstrates significant antiproliferative effects against HT-29 colon cancer and PANC-1 pancreatic cancer cell lines. However, human clinical trials for cancer applications are lacking, and most evidence remains at the laboratory level. Current research suggests immune-supporting effects, but larger controlled trials are needed to establish clinical efficacy.
Chelidonium majus contains hepatotoxic alkaloids that may cause liver damage with prolonged use or high doses. The herb can interact with immunosuppressive medications and may enhance or interfere with chemotherapy drugs due to its cellular effects. Pregnant and breastfeeding women should avoid use due to alkaloid content and potential teratogenic effects. Common side effects include gastrointestinal upset, and individuals with liver disease should exercise particular caution.
